Literature DB >> 1451813

Amputation level is not adversely affected by previous femorodistal bypass surgery.

T A Cook1, A H Davies, M Horrocks, R N Baird.   

Abstract

Data was reviewed on patients presenting with lower limb-threatening ischaemia to a single vascular unit between September 1984 and December 1990. Three hundred and thirty patients underwent either femoro-popliteal or femoro-infrapopliteal reconstructive surgery and 316 primary amputations were performed on 281 patients. Sixty-three secondary amputations were performed following a femoro-distal bypass failure. The below-knee amputation to above-knee amputation ratio (BKA/AKA) was 1.0 in the primary amputation group to 0.91 in the secondary amputation group. A direct comparison cannot be made as the patients represent two separate clinical groups. The ratio of reconstructive operations to primary amputations more than doubled between the first and second halves of the study. The BKA:AKA ratio in the secondary amputation group and the total number of secondary amputations remained relatively constant. This study supports the view that previous femoro-distal surgery does not adversely affect the overall outcome of amputation.

Entities:  

Mesh:

Year:  1992        PMID: 1451813     DOI: 10.1016/s0950-821x(05)80834-5

Source DB:  PubMed          Journal:  Eur J Vasc Surg        ISSN: 0950-821X


  3 in total

1.  Factors influencing the early outcome of major lower limb amputation for vascular disease.

Authors:  W B Campbell; S Marriott; R Eve; E Mapson; S Sexton; J F Thompson
Journal:  Ann R Coll Surg Engl       Date:  2001-09       Impact factor: 1.891

2.  Lower limb amputation: striking the balance.

Authors:  W B Campbell; J A St Johnston; V F Kernick; E A Rutter
Journal:  Ann R Coll Surg Engl       Date:  1994-05       Impact factor: 1.891

3.  Distal amputations: impact of the introduction of femorocrural and femoropedal arterial bypass.

Authors:  N R Borley; S Hettiaratchy; L Hands; J Collin
Journal:  Ann R Coll Surg Engl       Date:  1998-03       Impact factor: 1.891

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.